COPS7A Antibody

What is COPS7A and why is it a significant research target?

COPS7A (COP9 signalosome complex subunit 7a) is a key protein involved in cellular functions including protein ubiquitination and DNA repair. It functions as a subunit of the COP9 signalosome complex, playing a crucial role in regulating the stability and activity of various proteins involved in cell growth and proliferation. COPS7A is also known by several synonyms including CSN7, CSN7A, SGN7a, DERP10 (Dermal papilla-derived protein 10), and JAB1-containing signalosome subunit 7a.

Research significance: Dysregulation of COPS7A has been implicated in the development of cancer and other diseases, making it a promising target for therapeutic intervention. For example, studies have shown that COPS7A expression is downregulated in bladder cancer tissues compared to para-carcinoma tissues, suggesting its potential role as a tumor suppressor .

What applications are COPS7A antibodies validated for?

COPS7A antibodies have been validated for multiple research applications:

When designing experiments, researchers should verify the validation status of their specific antibody for their intended application, as validation can vary between manufacturers and antibody lots.

How should researchers validate COPS7A antibody specificity for their experimental systems?

Proper validation of COPS7A antibodies requires a multi-step approach:

• Protein array validation: Confirm specificity against a panel of human recombinant protein fragments. Some commercial antibodies have been tested against arrays containing the target protein plus 383 other non-specific proteins .

• Positive and negative controls: Use tissues or cell lines known to express or not express COPS7A. According to manufacturer data, positive samples include 293T, HepG2, NCI-H460, A-549, mouse brain, mouse heart, mouse kidney, rat heart, and rat kidney .

• Knockdown/knockout validation: Implement siRNA knockdown or CRISPR knockout of COPS7A, then confirm reduced signal with the antibody.

• Immunogen sequence verification: Check if the antibody was raised against a region conserved in your species of interest. For example, many COPS7A antibodies are raised against recombinant proteins corresponding to amino acids 1-275 of human COPS7A (NP_057403.1) .

• Multiple detection methods: Compare results across different methods (e.g., WB, IHC, and qPCR) to ensure consistent findings.

What are optimal conditions for Western blot analysis of COPS7A protein?

For optimal Western blot results when detecting COPS7A:

Sample preparation:

• Use appropriate lysis buffers containing protease inhibitors

• The calculated molecular weight of COPS7A is approximately 30 kDa (30,277 Da)

Running conditions:

• Use 10-12% SDS-PAGE gels for optimal resolution of COPS7A

• Include appropriate positive control samples (e.g., 293T, HepG2 cell lysates)

Transfer and detection:

• Standard PVDF or nitrocellulose membranes are suitable

• Recommended antibody dilutions range from 1:500 to 1:2000

• Use 5% BSA or non-fat milk for blocking

• For detection, both chemiluminescence and fluorescence-based methods work well

Controls:

• Always run positive control samples alongside experimental samples

• Consider running recombinant COPS7A protein as a standard

How can COPS7A antibodies be used to investigate its role in cancer pathways?

COPS7A has been implicated in cancer pathways, particularly in bladder cancer. Researchers can use COPS7A antibodies to:

• Expression profiling: Compare COPS7A expression levels between tumor and normal tissues using IHC, which has revealed significant downregulation in bladder cancer tissues .

• Mechanistic studies: Investigate the relationship between COPS7A and cell cycle regulators. After overexpression of LOC339524 (which increases COPS7A expression), researchers observed decreased expression of CDK2, CDK4, and cyclin D1 proteins .

• Signaling pathway analysis: Examine COPS7A's interaction with microRNA networks. Research has shown that COPS7A is targeted by miR-875-5p, and its expression is regulated by the lncRNA LOC339524, which acts as a competitive endogenous RNA (ceRNA) .

• Functional studies: Monitor changes in COPS7A expression following treatments or genetic manipulations. For instance, treatment with 5-Aza-2'-deoxycytidine led to upregulation of LOC339524, which subsequently increased COPS7A expression in bladder cancer cell lines .

• Prognostic investigations: Correlate COPS7A expression levels with clinical outcomes to evaluate its potential as a prognostic marker.

What approaches can be used to study COPS7A's role in the COP9 signalosome complex?

To study COPS7A within the context of the COP9 signalosome complex:

• Co-immunoprecipitation (Co-IP): Use COPS7A antibodies for IP followed by Western blot analysis to identify interacting partners within the COP9 signalosome complex.

• Proximity ligation assay (PLA): Visualize protein-protein interactions between COPS7A and other components of the COP9 signalosome complex at single-molecule resolution.

• Immunofluorescence co-localization: Combine COPS7A antibodies with antibodies against other COP9 components to analyze their co-localization in cells using confocal microscopy.

• ChIP-seq analysis: Study the role of the COP9 signalosome in transcriptional regulation by examining chromatin association.

• Protein degradation assays: Monitor how manipulation of COPS7A affects the degradation of known COP9 signalosome targets, as the complex plays a critical role in regulating protein ubiquitination.

What are common sources of variability in COPS7A antibody experiments and how can they be addressed?

Several factors can introduce variability in COPS7A antibody experiments:

• Antibody lot-to-lot variation:

  • Issue: Different lots may have varying affinities and specificities.

  • Solution: Validate each new lot against previous lots using established positive controls.

• Fixation conditions in IHC/ICC:

  • Issue: Overfixation can mask epitopes.

  • Solution: Optimize fixation time and conditions; consider antigen retrieval methods for formalin-fixed samples.

• Species cross-reactivity:

  • Issue: Despite claims of multi-species reactivity, performance may vary across species.

  • Solution: Validate antibodies separately for each species of interest.

• Expression level variations:

  • Issue: Low endogenous expression can lead to weak signals.

  • Solution: Use positive control samples with known COPS7A expression; consider concentration steps for low-abundance samples.

• Storage and handling:

  • Issue: Antibody degradation affecting performance.

  • Solution: Store antibodies according to manufacturer recommendations (-20°C for long-term storage, 4°C for short-term use); avoid repeated freeze-thaw cycles .

How should researchers reconcile contradictory COPS7A expression data across different detection methods?

When facing contradictory COPS7A expression data:

• Methodological validation:

  • Verify that each method is properly validated for COPS7A detection

  • Check antibody specifications for each method (some antibodies may be validated for WB but not IHC)

• Technical considerations:

  • For protein-level discrepancies between WB and IHC/ICC: Consider epitope accessibility in fixed tissues versus denatured proteins

  • For discrepancies between mRNA and protein levels: Investigate potential post-transcriptional regulation

• Biological context:

  • Cell/tissue type differences: COPS7A expression may vary by cell type

  • Subcellular localization: Consider whether the protein might be sequestered in different cellular compartments

• Quantitative analysis:

  • Use quantitative methods (qPCR, quantitative WB) with appropriate normalization

  • Calculate statistical significance of observed differences

• Independent validation:

  • Use multiple antibodies targeting different epitopes of COPS7A

  • Employ orthogonal methods such as mass spectrometry for validation

How can COPS7A expression analysis contribute to understanding cancer progression mechanisms?

Recent research has revealed several important roles for COPS7A in cancer:

• Tumor suppressor function: Studies have demonstrated that COPS7A expression is downregulated in bladder cancer tissues compared to para-carcinoma tissues, suggesting a potential tumor suppressor role .

• Regulatory RNA networks: COPS7A is regulated by a complex network involving lncRNA LOC339524 and miR-875-5p. LOC339524 functions as a competitive endogenous RNA (ceRNA) that promotes COPS7A expression by binding to miR-875-5p .

• Cell cycle regulation: COPS7A appears to influence cell cycle progression. When COPS7A expression was increased through LOC339524 overexpression, researchers observed decreased expression of cell cycle regulators CDK2, CDK4, and cyclin D1 .

• Epigenetic regulation: The downregulation of LOC339524 (which regulates COPS7A) in bladder cancer has been linked to hypermethylation of its promoter. Treatment with the demethylating agent 5-Aza-2'-deoxycytidine increased LOC339524 expression, subsequently affecting COPS7A levels .

• Proliferation inhibition: Functional studies suggest that increasing COPS7A expression (via the LOC339524/miR-875-5p axis) inhibits the proliferation of bladder cancer cells, highlighting its potential therapeutic importance .

What novel techniques are being developed for studying COPS7A protein interactions and modifications?

Emerging techniques for studying COPS7A include:

• Proximity-dependent biotinylation (BioID or TurboID): These techniques allow for identification of proteins that interact with COPS7A within living cells, providing a more physiologically relevant interactome.

• Single-cell proteomics: Advances in mass spectrometry sensitivity now allow for protein quantification at single-cell resolution, enabling studies of COPS7A expression heterogeneity within tissues.

• CRISPR-based screening: CRISPR screens can identify synthetic lethal interactions with COPS7A in cancer cells, potentially revealing new therapeutic targets.

• Live-cell imaging with tagged COPS7A: Using fluorescently tagged COPS7A expressed at endogenous levels via CRISPR knock-in allows for real-time monitoring of protein dynamics.

• Protein degradation technologies: Targeted protein degradation approaches (PROTACs, dTAGs) provide new ways to study the acute effects of COPS7A loss, complementing traditional knockdown approaches.

What are the optimal sample preparation methods for detecting COPS7A in different experimental contexts?

Sample preparation methods vary by application:

For Western blotting:

• Use RIPA or NP-40 lysis buffers with protease inhibitors

• Include phosphatase inhibitors if studying phosphorylation status

• Optimal protein amount: 20-50 μg total protein per lane

• Denature samples at 95°C for 5 minutes in Laemmli buffer

For immunohistochemistry:

• Formalin fixation (10% neutral buffered formalin for 24-48 hours)

• Paraffin embedding following standard protocols

• Section thickness: 4-5 μm recommended

• Antigen retrieval: Citrate buffer (pH 6.0) heat-induced epitope retrieval may be necessary

• Recommended dilutions: 1:20-1:50

For immunofluorescence:

• Fixation: 4% paraformaldehyde for 10-15 minutes at room temperature

• Permeabilization: 0.1-0.5% Triton X-100 for 5-10 minutes

• Blocking: 5% normal serum (match to secondary antibody host)

• Primary antibody concentration: 0.25-2 μg/ml

• Incubation: Overnight at 4°C or 1-2 hours at room temperature

How can researchers effectively use COPS7A antibodies in multiplex staining protocols?

For effective multiplex staining with COPS7A antibodies:

• Antibody selection:

  • Choose COPS7A antibodies raised in different host species than other target antibodies

  • Alternatively, use directly conjugated COPS7A antibodies when available

  • Consider using rabbit polyclonal anti-COPS7A as most available antibodies are rabbit-derived

• Staining protocol optimization:

  • Test antibodies individually before combining

  • Determine optimal concentration for each antibody

  • Consider sequential staining if cross-reactivity occurs

• Controls for multiplex staining:

  • Single-stain controls to ensure specificity

  • Secondary-only controls to assess background

  • Absorption controls to confirm specificity

• Detection systems:

  • Use spectrally distinct fluorophores for fluorescence microscopy

  • For chromogenic IHC, use different chromogens with good spectral separation

  • Consider tyramide signal amplification for low-abundance targets

• Analysis considerations:

  • Use appropriate software for spectral unmixing if needed

  • Quantify co-localization using specialized image analysis tools